Technology

  • 메인

  • Pipeline

Pipeline

We develop diverse therapeutics that can be applied in the treatment of
various indications related to inflamed and leaky blood vessels.

We have targeted ophthalmic diseases as our first indication and completed a joint research and technology transfer agreement with a global biotech company specializing in ophthalmic diseases, proving our unique technological strength and value. With the territory of ophthalmic diseases as our strategic foothold and new therapeutic candidates already secured, we have established a solid roadmap and portfolio that can be expanded into therapies for systemic diseases, including various forms of vasculitis, cancer, and kidney diseases.

Pipeline Discovery Pre-Clinical Phase I Phase II Phase III Remarks
Late Stage
Pipelines
IGT-427
[Various Ophthalmic Retinal Diseases]
• MSD’s core ophthalmic pipeline
• Ongoing Global Phase 3 Clinical Trials (NVAMD, DME)
IGT-427
IGT-427 is INGENIA's lead drug candidate developed using its proprietary LCIDEC platform technology and represents the company's first successfully out-licensed asset with blockbuster potential. It is a bispecific antibody differentiated from current standards of care (SoC) through its dual mechanism of action, simultaneously activating TIE2 and inhibiting vascular endothelial growth factor(VEGF).
IGT-303
[Chronic Kidney Disease (Diabetic Kidney Disease)]
• Ongoing Global Phase 2a Clinical Trials (Australia, New Zealand, South Korea)
IGT-303
IGT-303 is a drug candidate for chronic kidney disease (CKD) developed using INGENIA's TIE-body technology.
By activating TIE2 on glomerular microvascular endothelial cells, it promotes endothelial cell survival, enhances vascular stability, and reduces inflammation, thereby supporting the restoration of normal glomerular filtration function. With the potential for differentiated efficacy, improved patient convenience, and first-in-class positioning, IGT-303 represents a promising next-generation therapeutic candidate for CKD.
IGT-302
[Glaucoma]
• Joint research underway with MSD
IGT-302
IGT-302 is a drug candidate for glaucoma developed using INGENIA's proprietary TIE-body technology.
By restoring damage to Schlemm's canal, a key contributor to the pathogenesis of glaucoma, and directly activating TIE2, it has the potential to address the underlying cause of the disease. With the potential for first-in-class positioning, IGT-302 represents a promising next-generation therapeutic candidate for glaucoma.
Early Stage
Pipelines 		IGT-532
[Cancer]
• Phase 1 clinical trial planned for 2027
• Tri-specific antibody width VEGF/PD-1 inhibition & TIE2 activation
IGT-303
[Dementia]
• TIE2 activation mechanism
• As a Combination therapy for dementia
IGT-627
[Pulmonary Arterial Hypertension]
• TIE2 activation & anti-fibrosis/anti-modeling mechanism
• Joint research width Harvard Medical School/MGB Cardiovascular Center